SIMCERE PHARMAC. GRP LTD (S2P) - Total Assets
Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) holds total assets worth €14.73 Billion EUR (≈ $17.22 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SIMCERE PHARMAC. GRP LTD - Total Assets Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's total assets have evolved over time, based on quarterly financial data. Also see S2P market cap for the company's overall valuation and market capitalisation.
SIMCERE PHARMAC. GRP LTD - Asset Composition Analysis
Current Asset Composition (December 2025)
SIMCERE PHARMAC. GRP LTD's total assets of €14.73 Billion consist of 50.2% current assets and 49.8% non-current assets. Review S2P liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.9% |
| Accounts Receivable | €2.49 Billion | 16.9% |
| Inventory | €589.50 Million | 4.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.44 Billion | 9.8% |
| Goodwill | €142.47 Million | 1.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SIMCERE PHARMAC. GRP LTD stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SIMCERE PHARMAC. GRP LTD's current assets represent 50.2% of total assets in 2025, an increase from 49.0% in 2021.
- Cash Position: Cash and equivalents constituted 23.9% of total assets in 2025, up from 9.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 16.9% of total assets.
SIMCERE PHARMAC. GRP LTD Competitors by Total Assets
Key competitors of SIMCERE PHARMAC. GRP LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Dr. Reddy's Laboratories Limited
F:RDDA
|
Germany | €562.90 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
China | CN¥12.25 Billion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥22.22 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.70 Billion |
SIMCERE PHARMAC. GRP LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.01 | 2.10 |
| Quick Ratio | 2.03 | 1.80 | 1.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.04 Billion | €2.76 Billion | €3.36 Billion |
SIMCERE PHARMAC. GRP LTD - Advanced Valuation Insights
This section examines the relationship between SIMCERE PHARMAC. GRP LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.76 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 27.9% |
| Total Assets | €14.73 Billion |
| Market Capitalization | $3.17 Billion USD |
Valuation Analysis
Below Book Valuation: The market values SIMCERE PHARMAC. GRP LTD's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SIMCERE PHARMAC. GRP LTD's assets grew by 27.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual total assets of SIMCERE PHARMAC. GRP LTD from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.73 Billion ≈ $17.22 Billion |
+27.94% |
| 2024-12-31 | €11.51 Billion ≈ $13.46 Billion |
+6.05% |
| 2023-12-31 | €10.85 Billion ≈ $12.69 Billion |
+0.60% |
| 2022-12-31 | €10.79 Billion ≈ $12.61 Billion |
+6.18% |
| 2021-12-31 | €10.16 Billion ≈ $11.88 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more